Routine primary care data for scientific research, quality of care programs and educational purposes: the Julius General Practitioners’ Network (JGPN)

Smeets, Hugo M.; Kortekaas, Marlous F; Rutten, Frans H.; Bots, Michiel L.; Kraan, W. van der; Daggelders, Gerard; Smits-Pelser, Hanneke; Helsper, Charles W.; Hoes, Arno W.; Wit, Niek J. de

doi:10.1186/s12913-018-3528-5

Cited by 70 publications

(73 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We conducted a longitudinal drug utilization study in 6 countries between January 2008 and December 2015. Data were retrieved from the following 8 databases: (i) the Dutch Mondriaan project, which includes the Julius General Practitioner Network (JHN) database; (ii) the Danish National Registries (DNR), which includes the Danish National Patient Register, Danish National Prescription Registry and Danish Civil Registration System; (iii) the AOK Nordwest database, Germany; (iv) the Bavarian Association of Statutory Health Insurance Physicians database, referred to here as Bavarian CD, Germany; (v) the Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP), Spain; (vi) the Information System for the Development of Research in Primary Care (SIDIAP), Catalonia, Spain; (vii) the Clinical Practice Research Datalink (CPRD), UK; (viii) The Echantillon Généraliste de Bénéficiaires (EGB), France . The databases characteristics are described in Table .…”

Section: Methodsmentioning

confidence: 99%

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross‐national drug utilization study

Ibáñez

Sabaté

Vidal

et al. 2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimsTo estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries.MethodsLongitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed.ResultsA total of 186 405 new DOAC users (age ≥18 years) were identified. Standardized incidences varied from 1.93–2.60 and 0.11–8.71 users/10 000 (2011–2015) for dabigatran and rivaroxaban, respectively, and from 0.01–8.12 users/10 000 (2012–2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10 000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only 1 database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP) and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany).ConclusionOverall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as comorbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH).

show abstract

Section: Methodsmentioning

confidence: 99%

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross‐national drug utilization study

Ibáñez

Sabaté

Vidal

et al. 2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The United States is the single dominant country in the field, which is unsurprising given its population, wealth, and research resources and output. [64][65][66][67] The high standing of the United Kingdom and Netherlands despite smaller populations may be attributable to primary care data availability, 68,69 facilitated by high adoption rates of EHRs, 70 and strong information technology academics and industries. 71,72 Investments in data generation, quality, and access will increase future possibilities for AI to be used to strengthen primary care in the corresponding region.…”

Section: Key Findingsmentioning

confidence: 99%

Artificial Intelligence and Primary Care Research: A Scoping Review

et al. 2020

View full text Add to dashboard Cite

PURPOSE Rapid increases in technology and data motivate the application of artificial intelligence (AI) to primary care, but no comprehensive review exists to guide these efforts. Our objective was to assess the nature and extent of the body of research on AI for primary care. METHODSWe performed a scoping review, searching 11 published or gray literature databases with terms pertaining to AI (eg, machine learning, bayes* network) and primary care (eg, general pract*, nurse). We performed title and abstract and then full-text screening using Covidence. Studies had to involve research, include both AI and primary care, and be published in English. We extracted data and summarized studies by 7 attributes: purpose(s); author appointment(s); primary care function(s); intended end user(s); health condition(s); geographic location of data source; and AI subfield(s). RESULTSOf 5,515 unique documents, 405 met eligibility criteria. The body of research focused on developing or modifying AI methods (66.7%) to support physician diagnostic or treatment recommendations (36.5% and 13.8%), for chronic conditions, using data from higher-income countries. Few studies (14.1%) had even a single author with a primary care appointment. The predominant AI subfields were supervised machine learning (40.0%) and expert systems (22.2%).CONCLUSIONS Research on AI for primary care is at an early stage of maturity. For the field to progress, more interdisciplinary research teams with end-user engagement and evaluation studies are needed. Ann Fam Med 2020;18:250-258. https://doi.

show abstract

“…Julius General Practitioners Network (University Medical Centre Utrecht), healthcare network Almere (Zorggroep Almere) and the Registration Network of General Practitioners Associated with LeidenUniversity (RNUH-LEO) [9][10][11]. …”

mentioning

confidence: 99%

Effects of non‐dispensing pharmacists integrated in general practice on medication‐related hospitalisations

Sloeserwij

Hazen

Zwart

et al. 2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

To evaluate the effect of non-dispensing pharmacists (NDPs) integrated in general practice on medication-related hospitalisations, drug burden index and costs in patients at high risk of medication problems (being 65 years or older and using 5 or more chronic medications). Methods: This was a multicentre, nonrandomised, controlled intervention study with pre-post comparison (2013 vs June 2014 to May 2015) in 25 general practices in the Netherlands, comparing NDP-led care (intervention) with 2 current pharmaceutical care models (usual care and usual care plus). In the intervention group, 10 specially trained NDPs were employed in general practices to take integral responsibility for the pharmaceutical care. They provided a broad range of medication therapy management services both on patient level (e.g. clinical medication review) and practice level (e.g. quality improvement projects). In the control groups, pharmaceutical care was provided as usual by general practitioners and community pharmacists, or as usual plus, when pharmacists were additionally trained in performing medication reviews. Results: Overall, 822 medication-related hospitalisations were identified among 11 281 high-risk patients during the intervention period. After adjustment for clustering and potential confounders, the rate ratio of medication-related hospitalisations in the intervention group compared to usual care was 0.68 (95% confidence interval: 0.57-0.82) and 1.05 (95% confidence interval: 0.73-1.52) compared to usual care plus. No differences in drug burden index or costs were found. Conclusions: In general practices with an integrated NDP, the rate of medicationrelated hospitalisations is lower compared to usual care. No differences with usual care plus were found.

show abstract

Routine primary care data for scientific research, quality of care programs and educational purposes: the Julius General Practitioners’ Network (JGPN)

Cited by 70 publications

References 37 publications

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross‐national drug utilization study

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross‐national drug utilization study

Artificial Intelligence and Primary Care Research: A Scoping Review

Effects of non‐dispensing pharmacists integrated in general practice on medication‐related hospitalisations

Contact Info

Product

Resources

About